Evidence-based analysis of cancer treatment innovations, clinical trial design, and the science shaping modern oncology — written by a GCP-certified CRO team in the field.
From CAR-T expansion into solid tumours to the rise of antibody-drug conjugates and PROTAC degraders — a CRO's evidence-based guide to the treatment innovations changing outcomes this year.
Read the full article
How upfront biomarker strategy separates trials that show a signal from those that show a real treatment effect — and the statistical cost of getting it wrong.
A deep look at what platform trials actually do better, and what operational and regulatory complexity they introduce — with real-world cost and timelines.
The accumulating data linking metabolic syndrome, insulin resistance, and inflammatory pathways to lymphoma and leukaemia — and the trial design implications.
The regulatory and scientific rationale for pre-specified analysis — and the common protocol gaps that give regulators pause at submission.
What chronic lymphocytic leukaemia and small lymphocytic lymphoma actually mean, what to expect from staging conversations, and what treatment options look like.
Screening, consent, visits, and rights — everything you need to know before saying yes to a trial, in plain language without the jargon.